OGN vs TEM · P/E 3.4, rev $6.40B vs rev $1.27B
Organon & Co (OGN) versus Tempus AI, Inc. Class A Common Stock (TEM) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Tempus AI, Inc. Class A Common Stock (TEM) is a health information services company listed on NASDAQ.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported TEM revenue for 2025-12-31 was $1.27B. Net income was -$245.0M. Revenue was up 83.4% from 2024-12-31 to 2025-12-31. TEM currently screens at market cap $8.76B.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. TEM currently screens at market cap $8.76B.
Not investment advice. Open the OGN and TEM stock pages for the full models.
Not investment advice.